Glucose-Insulin-Potassium shows some benefit in acute coronary syndrome

Intravenous glucose-insulin-potassium (GIK) is postulated to be beneficial in acute ischaemic syndromes via two mechanisms: by providing metabolic support to ischaemic myocardium, and by preventing arrhythmias and cardiac arrest due to ischaemia-related metabolic derangements.¬† Importantly, these benefits are most likely to be seen if GIK is started as soon as possible after the onset of […]

Read More…